好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

The Classification of Autosomal Recessive Cerebellar Ataxias: A Consensus Statement from the Society for Research on the Cerebellum and Ataxias Task Force
Movement Disorders
S50 - Ataxia, Dystonia, and Atypical Parkinsonism (2:00 PM-2:12 PM)
006

The objective of this task force was to build a consensus on the classification of autosomal recessive ataxias in order to develop a general approach to a patient presenting with ataxia, organize disorders according to clinical presentation, and define this field of research by identifying common pathogenic molecular mechanisms in these disorders.

There is currently no accepted classification of autosomal recessive cerebellar ataxias, a group of disorders characterized by important genetic heterogeneity and complex phenotypes.

The work of this task force was based on a previously published systematic scoping review of the literature that identified autosomal recessive disorders characterized primarily by cerebellar motor dysfunction and cerebellar degeneration. The task force regrouped 12 international ataxia experts who decided on general orientation and specific issues.

We identified 59 disorders that are classified as primary autosomal recessive cerebellar ataxias. For each of these disorders, we present geographical and ethnical specificities along with distinctive clinical and imagery features. These primary recessive ataxias were organized in a clinical and a pathophysiological classification, and we present a general clinical approach to the patient presenting with ataxia. We also identified a list of 48 complex multisystem disorders that are associated with ataxia and should be included in the differential diagnosis of autosomal recessive ataxias.

This classification is the result of a consensus among a panel of international experts, and it promotes a unified understanding of autosomal recessive cerebellar disorders for clinicians and researchers.

Authors/Disclosures
Marie Beaudin, MD
PRESENTER
Dr. Beaudin has nothing to disclose.
No disclosure on file
Bing-Wen Soong, MD, PhD, FAAN No disclosure on file
Jose Luiz Pedroso, MD (Universidade Federal De Sao Paulo) Dr. Pedroso has nothing to disclose.
Orlando G. Barsottini, MD, PhD (Universidade Federal de São Paulo) Dr. Barsottini has nothing to disclose.
No disclosure on file
Shoji Tsuji, MD, PhD (University of Tokyo) The institution of Dr. Tsuji has received research support from Novelpharma Co. Ltd..
Jeremy D. Schmahmann, MD, FAAN (Massachusettes General Hospital) Dr. Schmahmann has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biohaven. The institution of Dr. Schmahmann has received research support from National Ataxia Foundation. The institution of Dr. Schmahmann has received research support from Biohaven. Dr. Schmahmann has received intellectual property interests from a discovery or technology relating to health care. Dr. Schmahmann has received publishing royalties from a publication relating to health care. Dr. Schmahmann has received publishing royalties from a publication relating to health care. Dr. Schmahmann has received publishing royalties from a publication relating to health care.
Mario Manto, MD, PhD (ULB, Dept of Neurology) No disclosure on file
Guy A. Rouleau, MD, PhD, FAAN (Montreal Neurological Institute and Hospital) Dr. Rouleau has received personal compensation in the range of $500-$4,999 for serving as a Consultant for NovoNordisk. Dr. Rouleau has received personal compensation in the range of $5,000-$9,999 for serving as an officer or member of the Board of Directors for AL-S Pharma.
Nicolas Dupre, MD, FAAN (CHU de Quebec - U Laval) Dr. Dupre has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Akcea Therapeutics Canada. The institution of Dr. Dupre has received research support from ARSACS Foundation. The institution of Dr. Dupre has received research support from CHUdeQuebec Foundation.